fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Summer Lifeguard Classes to be Held This Month

MUHLENBERG COUNTY, Ky. (5/5/15) — Lifeguard class dates this year are May 15, 16, 17, 23 and 24. Participants are… Read More

Lady Mustangs shut out Owensboro, 13-0

GREENVILLE, Ky. (5/6/15) - The Muhlenberg County Lady Mustangs rolled to a win at home on Tuesday, defeating the… Read More

Most Read This Week

April 28, 2015 4337

Search for Stolen Vehicle Ends with Woman Charged…

by SurfKY News
May 05, 2015 3793

Meth Charge Follows MPD Investigation into…

by SurfKY News
April 28, 2015 3484

Man Charged with Stalking Smoke Shop Clerk

by MPD
May 05, 2015 3401

School Board Studies Further Spending Cuts

by Charles W. Riley II, SurfKY News
April 30, 2015 2976

Family Says 'Goodbye' to Dog After It Allegedly…

by Doreen Dennis, SurfKY News

Most Read This Month

April 17, 2015 15973

An Open Letter from an Addict

by Olivia Kirks
April 23, 2015 8611

Man Charged with Sodomy, Incest/Victim under 12

by SurfKY News

Stories Trending Now

May 05, 2015 3793

Meth Charge Follows MPD Investigation into…

by SurfKY News
May 05, 2015 3401

School Board Studies Further Spending Cuts

by Charles W. Riley II, SurfKY News
May 06, 2015 1843

Gant Chosen as Pupil Personnel Director

by Tammy Holloway, SurfKY News
May 05, 2015 1221

Madisonville Man Goes to Hospital after…

by SurfKY News
May 05, 2015 1113

Two on Moped Injured in Collision with Car

by Doreen Dennis, SurfKY News
May 05, 2015 1104

Madisonville Police Arrest Reports - May 5, 2015

by SurfKY News
May 05, 2015 970

Baptist Health Madisonville Establishes Foundation

by Kristy J. Quinn
May 06, 2015 805

Hopkins Grand Jury Indictments Handed Down

by Karen McKnight
May 05, 2015 675

SurfKY Spotlight: First Kentucky Bank

by Gary Gates, SurfKY News
May 05, 2015 619

May 2015 In-House Rabies Clinics' Schedule

by Barry L. Franklin